Biocon Biologics Limited has published a detailed report that outlines strategic recommendations for increasing the adoption of biosimilars in low- and middle-income countries (LMICs). The report, developed in collaboration with Clarivate, offers insights into addressing healthcare challenges through affordable, quality-assured biosimilars. Key areas of focus include strengthening regulatory systems, promoting local manufacturing, and increasing awareness of biosimilars in LMICs.
With non-communicable diseases (NCDs) disproportionately impacting these regions, the adoption of biosimilars is crucial for expanding access to affordable treatments for conditions such as cancer and diabetes. Biocon’s study, published in the peer-reviewed GaBI Journal, emphasizes the importance of regulatory reforms and local manufacturing to expedite the availability of these life-saving therapies.
This initiative aligns with Biocon Biologics’ mission to enhance global healthcare accessibility, leveraging biosimilars to reduce costs and improve patient outcomes in underserved regions.
